ESMO Open最新文献

{"title":"29P Artificial intelligence and digital therapeutics: Enhancing predictive models for breast cancer treatment response","authors":"W. Ben Kridis, C. Belfekih Hassen, A. Khanfir","doi":"10.1016/j.esmoop.2026.106133","DOIUrl":"10.1016/j.esmoop.2026.106133","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106133"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"31P Swarm learning enables multi-center diffusion-based generative modeling for cancer imaging","authors":"J. Zhu","doi":"10.1016/j.esmoop.2026.106135","DOIUrl":"10.1016/j.esmoop.2026.106135","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106135"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"37P Fix the data, not the model: LMIC challenges in AI for precision oncology","authors":"H. Parupalli , R. Digumarti , K.C. Puligundla , R. Parimkayala , V. Toka","doi":"10.1016/j.esmoop.2026.106141","DOIUrl":"10.1016/j.esmoop.2026.106141","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106141"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"38eP AI-based identification of TKI-sensitive driver mutations using routine histopathology in lung adenocarcinoma","authors":"A. Ahmed , K. Nijjer","doi":"10.1016/j.esmoop.2026.106142","DOIUrl":"10.1016/j.esmoop.2026.106142","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106142"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"84eP Real-world clinical outcomes of lenvatinib plus pembrolizumab in advanced or recurrent endometrial cancer: A single-centre cohort study","authors":"M.M. Antony , A. Sadozye , K. Graham , R. Harrand , A. Kerr","doi":"10.1016/j.esmoop.2026.106225","DOIUrl":"10.1016/j.esmoop.2026.106225","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106225"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"87eP Association of HLA-A*01 status with inferior survival and response outcomes in early-phase clinical trial patients treated with immune checkpoint inhibitors","authors":"P.L. Villalba Cuesta , T.C. Hernandez Guerrero , B. Doger de Spéville , M. Pedregal Trujillo , E. Garcia Lorenzo , A. Rueda Lara , V. Moreno Garcia","doi":"10.1016/j.esmoop.2026.106228","DOIUrl":"10.1016/j.esmoop.2026.106228","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106228"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"10P Payload-centric determinants of sustained benefit from HER3-DXd and other TOP1-inhibitor ADCs in breast cancer: A systematic review of clinical, translational and preclinical evidence","authors":"L. Basmpana , S. Petousis , C. Margioula-Siarkou , K. Dinas","doi":"10.1016/j.esmoop.2026.106113","DOIUrl":"10.1016/j.esmoop.2026.106113","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106113"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"BRCA1 and BRCA2 pathogenic variants increase the risk of four less common cancer types","authors":"H. Sasagawa ,&nbsp;M. Endo ,&nbsp;Y. Iwasaki ,&nbsp;Y. Usui ,&nbsp;Y.N. Koyanagi ,&nbsp;G. Innella ,&nbsp;J. Hadler ,&nbsp;M.T. Parsons ,&nbsp;K. Numakura ,&nbsp;Y. Kamatani ,&nbsp;Y. Murakami ,&nbsp;K. Matsuo ,&nbsp;K. Matsuda ,&nbsp;A.B. Spurdle ,&nbsp;T. Habuchi ,&nbsp;Y. Momozawa","doi":"10.1016/j.esmoop.2026.106900","DOIUrl":"10.1016/j.esmoop.2026.106900","url":null,"abstract":"<div><h3>Background</h3><div>Previous family-based and case-control studies have expanded the cancer risk profile associated with pathogenic variants in <em>BRCA1</em> and <em>BRCA2</em>, providing the potential for expanding personalized medicine. Less common cancer types may benefit greatly from such expansion of genetic evidence because of their limited treatments and poor prognoses.</div></div><div><h3>Methods</h3><div>We conducted a case-control analysis of 3489 patients with nine less common cancer types (bladder, bone, brain, head and neck, sarcoma, skin, testis, thyroid, or ureteral cancer) and 38 842 controls without cancer to estimate the risk associated with <em>BRCA1</em> and <em>BRCA2</em> pathogenic variants of nine less common cancer types.</div></div><div><h3>Results</h3><div>We identified 105 pathogenic variants among 994 germline variants. We observed four significant associations: <em>BRCA1</em> with thyroid cancer [odds ratio (OR) 5.25, 95% confidence interval (CI) 2.06-13.38]; <em>BRCA2</em> with bladder (OR 4.67, 95% CI 2.57-8.47), head and neck (OR 3.89, 95% CI 2.01-7.53), and skin cancers (OR 6.13, 95% CI 2.47-15.24). For bladder cancer, the impact of <em>BRCA2</em> pathogenic variants was greater in females than in males (P_{heterogeneity} = 2.15 × 10⁻⁴; <em>I</em>^<em>2</em> = 92.70%).</div></div><div><h3>Conclusions</h3><div>These results provide evidence to inform more precise personalized medical options for individuals with <em>BRCA1</em> or <em>BRCA2</em> pathogenic variants.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106900"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial","authors":"G. Curigliano ,&nbsp;J. O’Shaughnessy ,&nbsp;F.-C. Bidard ,&nbsp;M.L. Casalnuovo ,&nbsp;S.-B. Kim ,&nbsp;E. Tokunaga ,&nbsp;P. Aftimos ,&nbsp;C. Saura ,&nbsp;L.A. Carey ,&nbsp;M. Okera ,&nbsp;E. Melo ,&nbsp;F. Zagouri ,&nbsp;M. Magallanes-Maciel ,&nbsp;N. Karadurmus ,&nbsp;S. Bahadur ,&nbsp;R.M. Speck ,&nbsp;X.A. Wang ,&nbsp;K. Pradhan ,&nbsp;J. Macey ,&nbsp;H. Kitchen ,&nbsp;N. Harbeck","doi":"10.1016/j.esmoop.2026.106945","DOIUrl":"10.1016/j.esmoop.2026.106945","url":null,"abstract":"<div><h3>Background</h3><div>Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen receptor degrader. In the phase III EMBER-3 trial, conducted in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer, imlunestrant demonstrated a significant progression-free survival benefit compared with standard endocrine therapy (standard of care; fulvestrant or exemestane) in patients harboring <em>ESR1</em> mutations (<em>ESR1</em>m). Additionally, the combination of imlunestrant and abemaciclib improved outcomes compared with imlunestrant monotherapy, irrespective of <em>ESR1</em>m status. This manuscript reports findings from exploratory analyses of patient-reported outcome (PRO) measures and qualitative interviews evaluating EMBER-3 participants’ experiences and treatment preferences.</div></div><div><h3>Materials and methods</h3><div>PROs administered were the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the PRO-Common Terminology Criteria for Adverse Events (CTCAE) items for diarrhea frequency and injection site reactions (for fulvestrant recipients only). Mean changes from baseline in EORTC QLQ-C30 scores were calculated using a longitudinal mixed model for repeated measures; a 10-point change defined as clinically meaningful. PRO-CTCAE analyses were descriptive. Interview transcripts were analyzed using directed content analysis techniques.</div></div><div><h3>Results</h3><div>Overall, global health status/quality of life (GHS/QoL) and function were generally maintained over time across treatment arms among the <em>ESR1</em>m population and all patients, with treatment differences favoring imlunestrant versus SOC among the <em>ESR1</em>m population. Fewer GHS/QoL and function deterioration events occurred in the imlunestrant arm (<em>ESR1</em>m and all patients) compared with other treatment arms. Most (72.3%) fulvestrant-treated patients reported injection site reactions at any time. Diarrhea frequency was consistently higher in the combination arm of imlunestrant–abemaciclib.</div></div><div><h3>Conclusion</h3><div>GHS/QoL and function were maintained across treatment arms, despite a higher incidence of diarrhea in the imlunestrant–abemaciclib group. These PRO findings complement the efficacy and safety results from EMBER-3 and further support the favorable risk–benefit profile of imlunestrant, either as oral monotherapy or in combination with abemaciclib, in patients with advanced breast cancer.</div></div>","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 4","pages":"Article 106945"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"6P TROP-2 as a therapeutical target in gastrointestinal tumors","authors":"L. Kabisch ,&nbsp;P.K.M. Hoffmeister-Wittmann ,&nbsp;S. Rogowski ,&nbsp;A. Manjunath ,&nbsp;L. Nader ,&nbsp;M. Gimmel ,&nbsp;C. Bienen ,&nbsp;D. Jäger ,&nbsp;M.T. Dill ,&nbsp;R. Jackstadt ,&nbsp;B. Köhler","doi":"10.1016/j.esmoop.2026.106109","DOIUrl":"10.1016/j.esmoop.2026.106109","url":null,"abstract":"","PeriodicalId":11877,"journal":{"name":"ESMO Open","volume":"11 ","pages":"Article 106109"},"PeriodicalIF":8.3,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147578609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}